5-Amino-1MQ
Research OnlyA small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
5-Amino-1-Methylquinolinium · NNMT Inhibitor
Mostly preclinical · 1 human study
- Preclinical
- 92%
- Clinical
- 8%
Based on 12 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth low: zero human trials, evidence is animal/in-vitro only with a small preclinical-foundation credit. Mechanism strong: NNMT target validated by knockout/knockdown and the NAD+/SAM-sirtuin-thermogenesis pathway is well mapped. Plausibility good: mechanism-to-surrogate chain coherent with NNMT overexpression in obese human adipose, but human outcome unproven. Global Coverage moderate: replicated across independent US and German groups, no regulatory recognition. Community Experience modest: niche enthusiast use, sparse and inconsistent reports. Effectiveness not-established — no quantified human efficacy estimate and no meaningful community effect signal.
The proposed mechanisms of 5-Amino-1MQ are based entirely on animal and in vitro studies. No human mechanistic data exists.
How It Works (Simplified)
5-Amino-1MQ acts by blocking NNMT, an enzyme that depletes important cellular resources:
Blocks NNMT enzyme activity, preventing it from consuming NAD+ precursors and SAM (the universal methyl donor).
Preserves nicotinamide for NAD+ synthesis, increasing cellular NAD+ levels especially in adipose tissue.
Higher NAD+ activates sirtuins (SIRT1-7), master regulators of metabolism, mitochondrial function, and energy expenditure.
In mice, leads to increased energy expenditure, adipose browning, and weight loss without reduced food intake.
Key Research: Neelakantan H et al. (UTMB, 2018) demonstrated that a potent, selective small-molecule NNMT inhibitor significantly reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake. PMID:29155147
Important Limitations
- Zero human trials - All efficacy data is from mice only
- Translation to human adipose tissue metabolism is unconfirmed
- Human pharmacokinetics (absorption, half-life, dosing) completely unknown
- NNMT expressed in multiple tissues (liver, brain, muscle) - systemic effects uncharacterized
- Potential cardiovascular concerns from vascular NNMT inhibition (NNMT may protect endothelium)
- No long-term safety data in any species
Based on preclinical data: NNMT inhibition should begin immediately upon administration. Mouse studies dosed NNMT inhibitors over multi-week treatment periods. No human pharmacokinetic data available to predict onset.
PMID:29155147In mouse studies, significant body-weight and white-adipose-mass reduction observed with NNMT-inhibitor treatment. Increased adipocyte NAD+ documented. Human timeline completely unknown.
PMID:29155147No long-term preclinical studies available. Sustained effects, tolerance development, and long-term metabolic adaptations are uncharacterized.
Completely unknown. Long-term safety and efficacy data do not exist in any species. Chronic NNMT inhibition effects unstudied.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Nmn
SynergisticTheoretical synergy: NMN provides NAD+ precursor while 5-Amino-1MQ preserves NAD+ by blocking NNMT consumption. Both aim to elevate NAD+ through complementary mechanisms. No combined studies available.
Nicotinamide-Riboside
SynergisticSimilar theoretical synergy as NMN. NR provides substrate for NAD+ synthesis while 5-Amino-1MQ reduces NAD+ depletion. Combined effects unstudied.
AOD-9604
CompatibleDifferent mechanisms of action (5-Amino-1MQ targets NNMT/NAD+ pathway vs AOD-9604's lipolytic effects). No interaction studies available; both target metabolic pathways through distinct routes.
Resveratrol
CompatibleBoth activate sirtuin pathways - resveratrol directly, 5-Amino-1MQ indirectly via NAD+ elevation. Theoretically complementary but unstudied.
Semaglutide
CautionBoth target metabolic and weight management pathways. Semaglutide is a GLP-1 agonist affecting appetite/insulin while 5-Amino-1MQ targets cellular NAD+ metabolism. No interaction data exists.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare 5-Amino-1MQ
Related Peptides
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Ecnoglutide
XW003 · Sciwind GLP-1
A long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.
Liraglutide
Victoza · Saxenda · NN2211
The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.